Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2022

Open Access 01-12-2022 | Cancer Therapy | Review

Circadian rhythms and cancers: the intrinsic links and therapeutic potentials

Authors: Li Zhou, Zhe Zhang, Edouard Nice, Canhua Huang, Wei Zhang, Yong Tang

Published in: Journal of Hematology & Oncology | Issue 1/2022

Login to get access

Abstract

The circadian rhythm is an evolutionarily conserved time-keeping system that comprises a wide variety of processes including sleep–wake cycles, eating–fasting cycles, and activity–rest cycles, coordinating the behavior and physiology of all organs for whole-body homeostasis. Acute disruption of circadian rhythm may lead to transient discomfort, whereas long-term irregular circadian rhythm will result in the dysfunction of the organism, therefore increasing the risks of numerous diseases especially cancers. Indeed, both epidemiological and experimental evidence has demonstrated the intrinsic link between dysregulated circadian rhythm and cancer. Accordingly, a rapidly increasing understanding of the molecular mechanisms of circadian rhythms is opening new options for cancer therapy, possibly by modulating the circadian clock. In this review, we first describe the general regulators of circadian rhythms and their functions on cancer. In addition, we provide insights into the mechanisms underlying how several types of disruption of the circadian rhythm (including sleep–wake, eating–fasting, and activity–rest) can drive cancer progression, which may expand our understanding of cancer development from the clock perspective. Moreover, we also summarize the potential applications of modulating circadian rhythms for cancer treatment, which may provide an optional therapeutic strategy for cancer patients.
Literature
1.
Patke A, Young MW, Axelrod S. Molecular mechanisms and physiological importance of circadian rhythms. Nat Rev Mol Cell Biol. 2020;21:67–84.PubMedCrossRef
2.
Roenneberg T, Merrow M. Circadian clocks—the fall and rise of physiology. Nat Rev Mol Cell Biol. 2005;6:965–71.PubMedCrossRef
3.
Winfree AT. Acute temperature sensitivity of the circadian rhythm in Drosophila. J Insect Physiol. 1972;18:181–5.CrossRef
4.
Zimmerman WF, Pittendrigh CS, Pavlidis T. Temperature compensation of the circadian oscillation in Drosophila pseudoobscura and its entrainment by temperature cycles. J Insect Physiol. 1968;14:669–84.PubMedCrossRef
5.
6.
Dunlap JC, Loros JJ, Liu Y, Crosthwaite SK. Eukaryotic circadian systems: cycles in common. Genes Cells. 1999;4:01–10.CrossRef
7.
Gekakis N, Staknis D, Nguyen HB, Davis FC, Wilsbacher LD, King DP, Takahashi JS, Weitz CJ. Role of the CLOCK protein in the mammalian circadian mechanism. Science. 1998;280:1564–9.PubMedCrossRef
8.
Honma S, Ikeda M, Abe H, Tanahashi Y, Namihira M, Honma K-I, Nomura M. Circadian oscillation ofBMAL1, a partner of a mammalian clock GeneClock, in rat suprachiasmatic nucleus. Biochem Biophys Res Commun. 1998;250:83–7.PubMedCrossRef
9.
Liu C, Weaver DR, Strogatz SH, Reppert SM. Cellular construction of a circadian clock: period determination in the suprachiasmatic nuclei. Cell. 1997;91:855–60.PubMedCrossRef
10.
Reinke H, Asher G. Crosstalk between metabolism and circadian clocks. Nat Rev Mol Cell Biol. 2019;20:227–41.PubMedCrossRef
11.
12.
13.
14.
15.
16.
Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Altieri A, Benbrahim-Tallaa L, Cogliano V, Group WIAfRoCMW. Carcinogenicity of shift-work, painting, and fire-fighting. Elsevier; 2007.CrossRef
17.
Stevens RG, Hansen J, Costa G, Haus E, Kauppinen T, Aronson KJ, Castaño-Vinyals G, Davis S, Frings-Dresen MH, Fritschi L. Considerations of circadian impact for defining ‘shift work’in cancer studies: IARC working group report. Occup Environ Med. 2011;68:154–62.PubMedCrossRef
18.
Lin H-H, Farkas ME. Altered circadian rhythms and breast cancer: from the human to the molecular level. Front Endocrinol (Lausanne). 2018;9:219.CrossRef
19.
Wendeu-Foyet MG, Menegaux F. Circadian disruption and prostate cancer risk: an updated review of epidemiological evidences. Cancer Epidemiol Biomark Prev. 2017;26:985–91.CrossRef
20.
Innominato PF, Focan C, Gorlia T, Moreau T, Garufi C, Waterhouse J, Giacchetti S, Coudert B, Iacobelli S, Genet D. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res. 2009;69:4700–7.PubMedPubMedCentralCrossRef
21.
Bishehsari F, Levi F, Turek FW, Keshavarzian A. Circadian rhythms in GI health and diseases. Gastroenterology. 2016;151:e1.PubMedCrossRef
22.
Tahara Y, Shibata S. Circadian rhythms of liver physiology and disease: experimental and clinical evidence. Nat Rev Gastroenterol Hepatol. 2016;13:217.PubMedCrossRef
23.
Papagiannakopoulos T, Bauer MR, Davidson SM, Heimann M, Subbaraj L, Bhutkar A, Bartlebaugh J, Vander Heiden MG, Jacks T. Circadian rhythm disruption promotes lung tumorigenesis. Cell Metab. 2016;24:324–31. PubMedPubMedCentralCrossRef
24.
Voigt RM, Forsyth CB, Green SJ, Engen PA, Keshavarzian A. Circadian rhythm and the gut microbiome. Int Rev Neurobiol. 2016;131:193–205.PubMedCrossRef
25.
26.
27.
Kelleher FC, Rao A, Maguire A. Circadian molecular clocks and cancer. Cancer Lett. 2014;342:9–18.PubMedCrossRef
28.
29.
Ozturk N, Ozturk D, Kavakli IH, Okyar A. Molecular aspects of circadian pharmacology and relevance for cancer chronotherapy. Int J Mol Sci. 2017;18:2168.PubMedCentralCrossRef
30.
Rosenwasser AM, Turek FW. Neurobiology of circadian rhythm regulation. Sleep Med Clin. 2015;10:403–12.PubMedCrossRef
31.
Hastings MH, Maywood ES, Brancaccio M. Generation of circadian rhythms in the suprachiasmatic nucleus. Nat Rev Neurosci. 2018;19:453–69.PubMedCrossRef
32.
Shearman LP, Sriram S, Weaver DR, Maywood ES, Chaves I, Zheng B, Kume K, Lee CC, van der Horst GT, Hastings MH, et al. Interacting molecular loops in the mammalian circadian clock. Science. 2000;288:1013–9.PubMedCrossRef
33.
Haque SN, Booreddy SR, Welsh DK. Effects of BMAL1 manipulation on the brain’s master circadian clock and behavior. Yale J Biol Med. 2019;92:251–8.PubMedPubMedCentral
34.
Kondratov RV, Shamanna RK, Kondratova AA, Gorbacheva VY, Antoch MP. Dual role of the CLOCK/BMAL1 circadian complex in transcriptional regulation. FASEB J. 2006;20:530–2.PubMedCrossRef
35.
Vielhaber EL, Duricka D, Ullman KS, Virshup DM. Nuclear export of mammalian PERIOD proteins. J Biol Chem. 2001;276:45921–7.PubMedCrossRef
36.
Akashi M, Okamoto A, Tsuchiya Y, Todo T, Nishida E, Node K. A positive role for PERIOD in mammalian circadian gene expression. Cell Rep. 2014;7:1056–64.PubMedCrossRef
37.
Schmalen I, Reischl S, Wallach T, Klemz R, Grudziecki A, Prabu JR, Benda C, Kramer A, Wolf E. Interaction of circadian clock proteins CRY1 and PER2 is modulated by zinc binding and disulfide bond formation. Cell. 2014;157:1203–15.PubMedCrossRef
38.
39.
Ukai-Tadenuma M, Kasukawa T, Ueda HR. Proof-by-synthesis of the transcriptional logic of mammalian circadian clocks. Nat Cell Biol. 2008;10:1154–63.PubMedCrossRef
40.
Duez H, Staels B. Rev-erb-alpha: an integrator of circadian rhythms and metabolism. J Appl Physiol. 1985;2009(107):1972–80.
41.
Ikeda R, Tsuchiya Y, Koike N, Umemura Y, Inokawa H, Ono R, Inoue M, Sasawaki Y, Grieten T, Okubo N, et al. REV-ERBalpha and REV-ERBbeta function as key factors regulating Mammalian Circadian Output. Sci Rep. 2019;9:10171.PubMedPubMedCentralCrossRef
42.
Jetten AM. Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. Nucl Recept Signal. 2009;7:e003.PubMedPubMedCentralCrossRef
43.
Reszka E, Przybek M, Muurlink O, Peplonska B. Circadian gene variants and breast cancer. Cancer Lett. 2017;390:137–45.PubMedCrossRef
44.
Morgan MN, Dvuchbabny S, Martinez CA, Kerr B, Cistulli PA, Cook KM. The cancer clock is (not) ticking: links between circadian rhythms and cancer. Clocks Sleep. 2019;1:435–58.PubMedPubMedCentralCrossRef
45.
Chu LW, Till C, Yang B, Tangen CM, Goodman PJ, Yu K, Zhu Y, Han S, Hoque AM, Ambrosone C, et al. Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog. 2018;57:462–6.PubMedPubMedCentralCrossRef
46.
47.
48.
Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Altieri A, Benbrahim-Tallaa L, Cogliano V. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 2007;8:1065–6.PubMedCrossRef
49.
Salamanca-Fernández E, Rodríguez-Barranco M, Guevara M, Ardanaz E, Olry de Labry Lima A, Sánchez MJ. Night-shift work and breast and prostate cancer risk: updating the evidence from epidemiological studies. An Sist Sanit Navar. 2018;41:211–26.PubMedCrossRef
50.
Gehlert S, Clanton M, On Behalf Of The Shift W, Breast Cancer Strategic Advisory G. Shift work and breast cancer. Int J Environ Res Public Health. 2020;17:9544.PubMedCentralCrossRef
51.
52.
Travis RC, Balkwill A, Fensom GK, Appleby PN, Reeves GK, Wang XS, Roddam AW, Gathani T, Peto R, Green J, et al. Night shift work and breast cancer incidence: three prospective studies and meta-analysis of published studies. J Natl Cancer Inst. 2016;108:djw169.PubMedPubMedCentralCrossRef
53.
Kogevinas M, Espinosa A, Castelló A, Gómez-Acebo I, Guevara M, Martin V, Amiano P, Alguacil J, Peiro R, Moreno V, et al. Effect of mistimed eating patterns on breast and prostate cancer risk (MCC-Spain Study). Int J Cancer. 2018;143:2380–9.PubMedPubMedCentralCrossRef
54.
Marinac CR, Natarajan L, Sears DD, Gallo LC, Hartman SJ, Arredondo E, Patterson RE. Prolonged nightly fasting and breast cancer risk: findings from NHANES (2009–2010). Cancer Epidemiol Biomark Prev. 2015;24:783–9.CrossRef
55.
Mormont MC, Waterhouse J, Bleuzen P, Giacchetti S, Jami A, Bogdan A, Lellouch J, Misset JL, Touitou Y, Lévi F. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 2000;6:3038–45.PubMed
56.
Innominato PF, Komarzynski S, Palesh OG, Dallmann R, Bjarnason GA, Giacchetti S, Ulusakarya A, Bouchahda M, Haydar M, Ballesta A, et al. Circadian rest-activity rhythm as an objective biomarker of patient-reported outcomes in patients with advanced cancer. Cancer Med. 2018;7:4396–405.PubMedPubMedCentralCrossRef
57.
Wood PA, Yang X, Taber A, Oh EY, Ansell C, Ayers SE, Al-Assaad Z, Carnevale K, Berger FG, Peña MM, et al. Period 2 mutation accelerates ApcMin/+ tumorigenesis. Mol Cancer Res. 2008;6:1786–93.PubMedPubMedCentralCrossRef
58.
Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002;111:41–50.PubMedCrossRef
59.
60.
Lee S, Donehower LA, Herron AJ, Moore DD, Fu L. Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice. PLoS ONE. 2010;5:e10995.PubMedPubMedCentralCrossRef
61.
Ueda E, Kurebayashi S, Sakaue M, Backlund M, Koller B, Jetten AM. High incidence of T-cell lymphomas in mice deficient in the retinoid-related orphan receptor RORgamma. Cancer Res. 2002;62:901–9.PubMed
62.
Gu X, Xing L, Shi G, Liu Z, Wang X, Qu Z, Wu X, Dong Z, Gao X, Liu G, et al. The circadian mutation PER2(S662G) is linked to cell cycle progression and tumorigenesis. Cell Death Differ. 2012;19:397–405.PubMedCrossRef
63.
Antoch MP, Gorbacheva VY, Vykhovanets O, Toshkov IA, Kondratov RV, Kondratova AA, Lee C, Nikitin AY. Disruption of the circadian clock due to the Clock mutation has discrete effects on aging and carcinogenesis. Cell Cycle. 2008;7:1197–204.PubMedCrossRef
64.
Antoch MP, Toshkov I, Kuropatwinski KK, Jackson M. Deficiency in PER proteins has no effect on the rate of spontaneous and radiation-induced carcinogenesis. Cell Cycle. 2013;12:3673–80.PubMedPubMedCentralCrossRef
65.
Janich P, Pascual G, Merlos-Suárez A, Batlle E, Ripperger J, Albrecht U, Cheng HY, Obrietan K, Di Croce L, Benitah SA. The circadian molecular clock creates epidermal stem cell heterogeneity. Nature. 2011;480:209–14.PubMedCrossRef
66.
Puram RV, Kowalczyk MS, de Boer CG, Schneider RK, Miller PG, McConkey M, Tothova Z, Tejero H, Heckl D, Järås M, et al. Core circadian clock genes regulate leukemia stem cells in AML. Cell. 2016;165:303–16.PubMedPubMedCentralCrossRef
67.
Disruption of core circadian clock genes reduces leukemia growth. Cancer Discov. 2016;6:569.
68.
Lee JH, Gaddameedhi S, Ozturk N, Ye R, Sancar A. DNA damage-specific control of cell death by cryptochrome in p53-mutant ras-transformed cells. Cancer Res. 2013;73:785–91.PubMedCrossRef
69.
Chan AB, Parico GCG, Fribourgh JL, Ibrahim LH, Bollong MJ, Partch CL, Lamia KA. CRY2 missense mutations suppress P53 and enhance cell growth. Proc Natl Acad Sci USA. 2021;118:4077.CrossRef
70.
Lange T, Dimitrov S, Born J. Effects of sleep and circadian rhythm on the human immune system. Ann N Y Acad Sci. 2010;1193:48–59.PubMedCrossRef
71.
Petrovsky N. Towards a unified model of neuroendocrine-immune interaction. Immunol Cell Biol. 2001;79:350–7.PubMedCrossRef
72.
73.
Liu X, Chen B, Huang Z, Duan R, Li H, Xie L, Wang R, Li Z, Gao Y, Zheng Y, et al. Effects of poor sleep on the immune cell landscape as assessed by single-cell analysis. Commun Biol. 2021;4:1325.PubMedPubMedCentralCrossRef
74.
Brooks JF 2nd, Behrendt CL, Ruhn KA, Lee S, Raj P, Takahashi JS, Hooper LV. The microbiota coordinates diurnal rhythms in innate immunity with the circadian clock. Cell. 2021;184:4154-67.e12.PubMedCrossRefPubMedCentral
75.
Dimitrov S, Lange T, Fehm HL, Born J. A regulatory role of prolactin, growth hormone, and corticosteroids for human T-cell production of cytokines. Brain Behav Immun. 2004;18:368–74.PubMedCrossRef
76.
Dimitrov S, Lange T, Tieken S, Fehm HL, Born J. Sleep associated regulation of T helper 1/T helper 2 cytokine balance in humans. Brain Behav Immun. 2004;18:341–8.PubMedCrossRef
77.
Lange T, Dimitrov S, Fehm HL, Westermann J, Born J. Shift of monocyte function toward cellular immunity during sleep. Arch Intern Med. 2006;166:1695–700.PubMedCrossRef
78.
Irwin M, Mascovich A, Gillin JC, Willoughby R, Pike J, Smith TL. Partial sleep deprivation reduces natural killer cell activity in humans. Psychosom Med. 1994;56:493–8.PubMedCrossRef
79.
Irwin M, McClintick J, Costlow C, Fortner M, White J, Gillin JC. Partial night sleep deprivation reduces natural killer and cellular immune responses in humans. FASEB J. 1996;10:643–53.PubMedCrossRef
80.
Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Fuchs CS, Colditz GA. Night-shift work and risk of colorectal cancer in the nurses’ health study. J Natl Cancer Inst. 2003;95:825–8.PubMedCrossRef
81.
Schernhammer ES, Razavi P, Li TY, Qureshi AA, Han J. Rotating night shifts and risk of skin cancer in the nurses’ health study. J Natl Cancer Inst. 2011;103:602–6.PubMedPubMedCentralCrossRef
82.
Papantoniou K, Devore EE, Massa J, Strohmaier S, Vetter C, Yang L, Shi Y, Giovannucci E, Speizer F, Schernhammer ES. Rotating night shift work and colorectal cancer risk in the nurses’ health studies. Int J Cancer. 2018;143:2709–17.PubMedPubMedCentralCrossRef
83.
Irwin MR, Wang M, Campomayor CO, Collado-Hidalgo A, Cole S. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch Intern Med. 2006;166:1756–62.PubMedCrossRef
84.
Irwin MR, Wang M, Ribeiro D, Cho HJ, Olmstead R, Breen EC, Martinez-Maza O, Cole S. Sleep loss activates cellular inflammatory signaling. Biol Psychiatry. 2008;64:538–40.PubMedPubMedCentralCrossRef
85.
Dimitrov S, Lange T, Benedict C, Nowell MA, Jones SA, Scheller J, Rose-John S, Born J. Sleep enhances IL-6 trans-signaling in humans. FASEB J. 2006;20:2174–6.PubMedCrossRef
86.
van Leeuwen WM, Lehto M, Karisola P, Lindholm H, Luukkonen R, Sallinen M, Härmä M, Porkka-Heiskanen T, Alenius H. Sleep restriction increases the risk of developing cardiovascular diseases by augmenting proinflammatory responses through IL-17 and CRP. PLoS ONE. 2009;4:e4589.PubMedPubMedCentralCrossRef
87.
Puttonen S, Kivimäki M, Elovainio M, Pulkki-Råback L, Hintsanen M, Vahtera J, Telama R, Juonala M, Viikari JS, Raitakari OT, et al. Shift work in young adults and carotid artery intima-media thickness: The Cardiovascular Risk in Young Finns study. Atherosclerosis. 2009;205:608–13.PubMedCrossRef
88.
Irwin MR. Sleep and inflammation: partners in sickness and in health. Nat Rev Immunol. 2019;19:702–15.PubMedCrossRef
89.
Vgontzas AN, Papanicolaou DA, Bixler EO, Lotsikas A, Zachman K, Kales A, Prolo P, Wong ML, Licinio J, Gold PW, et al. Circadian interleukin-6 secretion and quantity and depth of sleep. J Clin Endocrinol Metab. 1999;84:2603–7.PubMedCrossRef
90.
Dimitrov S, Besedovsky L, Born J, Lange T. Differential acute effects of sleep on spontaneous and stimulated production of tumor necrosis factor in men. Brain Behav Immun. 2015;47:201–10.PubMedCrossRef
91.
Redwine L, Dang J, Hall M, Irwin M. Disordered sleep, nocturnal cytokines, and immunity in alcoholics. Psychosom Med. 2003;65:75–85.PubMedCrossRef
92.
Redwine L, Hauger RL, Gillin JC, Irwin M. Effects of sleep and sleep deprivation on interleukin-6, growth hormone, cortisol, and melatonin levels in humans. J Clin Endocrinol Metab. 2000;85:3597–603.PubMed
93.
94.
Mullington JM, Haack M, Toth M, Serrador JM, Meier-Ewert HK. Cardiovascular, inflammatory, and metabolic consequences of sleep deprivation. Prog Cardiovasc Dis. 2009;51:294–302.PubMedPubMedCentralCrossRef
95.
96.
Kuhs H, Farber D, Tolle R. Serum prolactin, growth hormone, total corticoids, thyroid hormones and thyrotropine during serial therapeutic sleep deprivation. Biol Psychiatry. 1996;39:857–64.PubMedCrossRef
97.
Spiegel K, Leproult R, L’Hermite-Balériaux M, Copinschi G, Penev PD, Van Cauter E. Leptin levels are dependent on sleep duration: relationships with sympathovagal balance, carbohydrate regulation, cortisol, and thyrotropin. J Clin Endocrinol Metab. 2004;89:5762–71.PubMedCrossRef
98.
Morgan L, Hampton S, Gibbs M, Arendt J. Circadian aspects of postprandial metabolism. Chronobiol Int. 2003;20:795–808.PubMedCrossRef
99.
Knutsson A, Hammar N, Karlsson B. Shift workers’ mortality scrutinized. Chronobiol Int. 2004;21:1049–53.PubMedCrossRef
100.
Tanaka K, Sakata K, Oishi M, Morimoto H, Nakada S, Uetani M, Nogawa K, Suwazono Y. Estimation of the benchmark duration of shiftwork associated with weight gain in male Japanese workers. Chronobiol Int. 2010;27:1895–910.PubMedCrossRef
101.
Karlsson B, Knutsson A, Lindahl B. Is there an association between shift work and having a metabolic syndrome? Results from a population based study of 27,485 people. Occup Environ Med. 2001;58:747–52.PubMedPubMedCentralCrossRef
102.
van Amelsvoort LG, Schouten EG, Kok FJ. Duration of shiftwork related to body mass index and waist to hip ratio. Int J Obes Relat Metab Disord. 1999;23:973–8.PubMedCrossRef
103.
Yoshida J, Eguchi E, Nagaoka K, Ito T, Ogino K. Association of night eating habits with metabolic syndrome and its components: a longitudinal study. BMC Public Health. 2018;18:1366.PubMedPubMedCentralCrossRef
104.
Al-Aubaidy HA, Jelinek HF. Oxidative DNA damage and obesity in type 2 diabetes mellitus. Eur J Endocrinol. 2011;164:899–904.PubMedCrossRef
105.
Ligibel J. Obesity and breast cancer. Oncology (Williston Park). 2011;25:994–1000.
106.
107.
Srinivas US, Tan BWQ, Vellayappan BA, Jeyasekharan AD. ROS and the DNA damage response in cancer. Redox Biol. 2019;25:101084.PubMedCrossRef
108.
109.
110.
111.
Majidinia M, Sadeghpour A, Mehrzadi S, Reiter RJ, Khatami N, Yousefi B. Melatonin: A pleiotropic molecule that modulates DNA damage response and repair pathways. J Pineal Res. 2017;63:e12416.CrossRef
112.
Wei T, Li C, Heng Y, Gao X, Zhang G, Wang H, Zhao X, Meng Z, Zhang Y, Hou H. Association between night-shift work and level of melatonin: systematic review and meta-analysis. Sleep Med. 2020;75:502–9.PubMedCrossRef
113.
Bhatti P, Mirick DK, Randolph TW, Gong J, Buchanan DT, Zhang JJ, Davis S. Oxidative DNA damage during sleep periods among nightshift workers. Occup Environ Med. 2016;73:537–44.PubMedCrossRef
114.
Bhatti P, Mirick DK, Randolph TW, Gong J, Buchanan DT, Zhang JJ, Davis S. Oxidative DNA damage during night shift work. Occup Environ Med. 2017;74:680–3.PubMedCrossRef
115.
Cheung V, Yuen VM, Wong GTC, Choi SW. The effect of sleep deprivation and disruption on DNA damage and health of doctors. Anaesthesia. 2019;74:434–40.PubMedCrossRef
116.
Koritala BSC, Porter KI, Arshad OA, Gajula RP, Mitchell HD, Arman T, Manjanatha MG, Teeguarden J, Van Dongen HPA, McDermott JE, et al. Night shift schedule causes circadian dysregulation of DNA repair genes and elevated DNA damage in humans. J Pineal Res. 2021;70:e12726.PubMedCrossRefPubMedCentral
117.
Ashok Kumar PV, Dakup PP, Sarkar S, Modasia JB, Motzner MS, Gaddameedhi S. It’s about time: advances in understanding the circadian regulation of DNA damage and repair in carcinogenesis and cancer treatment outcomes. Yale J Biol Med. 2019;92:305–16.PubMedPubMedCentral
118.
Zada D, Sela Y, Matosevich N, Monsonego A, Lerer-Goldshtein T, Nir Y, Appelbaum L. Parp1 promotes sleep, which enhances DNA repair in neurons. Mol Cell. 2021;81:4979-4993.e7.PubMedCrossRef
119.
Vaccaro A, Kaplan Dor Y, Nambara K, Pollina EA, Lin C, Greenberg ME, Rogulja D. Sleep loss can cause death through accumulation of reactive oxygen species in the gut. Cell. 2020;181:1307-28.e15.PubMedCrossRef
120.
Neuzillet C, Tijeras-Raballand A, Cohen R, Cros J, Faivre S, Raymond E, de Gramont A. Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther. 2015;147:22–31.PubMedCrossRef
121.
122.
Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46–56.PubMedPubMedCentralCrossRef
123.
Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA. 2003;100:2645–50.PubMedPubMedCentralCrossRef
124.
Liu X, Nemeth DP, McKim DB, Zhu L, DiSabato DJ, Berdysz O, Gorantla G, Oliver B, Witcher KG, Wang Y, et al. Cell-type-specific interleukin 1 receptor 1 signaling in the brain regulates distinct neuroimmune activities. Immunity. 2019;50:317-33.e6.PubMedPubMedCentralCrossRef
125.
126.
Imeri L, Opp MR, Krueger JM. An IL-1 receptor and an IL-1 receptor antagonist attenuate muramyl dipeptide- and IL-1-induced sleep and fever. Am J Physiol. 1993;265:R907–13.PubMed
127.
Opp MR, Krueger JM. Anti-interleukin-1 beta reduces sleep and sleep rebound after sleep deprivation in rats. Am J Physiol. 1994;266:R688–95.PubMed
128.
Alam MN, McGinty D, Bashir T, Kumar S, Imeri L, Opp MR, Szymusiak R. Interleukin-1beta modulates state-dependent discharge activity of preoptic area and basal forebrain neurons: role in sleep regulation. Eur J Neurosci. 2004;20:207–16.PubMedCrossRef
129.
Kapás L, Shibata M, Kimura M, Krueger JM. Inhibition of nitric oxide synthesis suppresses sleep in rabbits. Am J Physiol. 1994;266:R151–7.PubMed
130.
Takahashi S, Kapás L, Fang J, Krueger JM. Somnogenic relationships between tumor necrosis factor and interleukin-1. Am J Physiol. 1999;276:R1132–40.PubMed
131.
Bauer J, Hohagen F, Ebert T, Timmer J, Ganter U, Krieger S, Lis S, Postler E, Voderholzer U, Berger M. Interleukin-6 serum levels in healthy persons correspond to the sleep-wake cycle. Clin Investig. 1994;72:315.PubMedCrossRef
132.
Späth-Schwalbe E, Hansen K, Schmidt F, Schrezenmeier H, Marshall L, Burger K, Fehm HL, Born J. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab. 1998;83:1573–9.PubMed
133.
Opp M, Obal F Jr, Cady AB, Johannsen L, Krueger JM. Interleukin-6 is pyrogenic but not somnogenic. Physiol Behav. 1989;45:1069–72.PubMedCrossRef
134.
Hogan D, Morrow JD, Smith EM, Opp MR. Interleukin-6 alters sleep of rats. J Neuroimmunol. 2003;137:59–66.PubMedCrossRef
135.
Bryant PA, Trinder J, Curtis N. Sick and tired: does sleep have a vital role in the immune system? Nat Rev Immunol. 2004;4:457–67.PubMedCrossRef
136.
Irwin M. Effects of sleep and sleep loss on immunity and cytokines. Brain Behav Immun. 2002;16:503–12.PubMedCrossRef
137.
Kerr J, Anderson C, Lippman SM. Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence. Lancet Oncol. 2017;18:e457–71.PubMedCrossRef
138.
Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera EV, Gapstur S, Patel AV, Andrews K, Gansler T. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2012;62:30–67.PubMedCrossRef
139.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.PubMedCrossRef
140.
Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A, Pistoia V, Wei M, Hwang S, Merlino A, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. 2012;4:124ra27.PubMedPubMedCentralCrossRef
141.
Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi G, Longo VD. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci USA. 2008;105:8215–20.PubMedPubMedCentralCrossRef
142.
Jardé T, Perrier S, Vasson MP, Caldefie-Chézet F. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer. 2011;47:33–43.PubMedCrossRef
143.
Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12:159–69.PubMedCrossRef
144.
Lee C, Safdie FM, Raffaghello L, Wei M, Madia F, Parrella E, Hwang D, Cohen P, Bianchi G, Longo VD. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res. 2010;70:1564–72.PubMedPubMedCentralCrossRef
145.
Cheng CW, Adams GB, Perin L, Wei M, Zhou X, Lam BS, Da Sacco S, Mirisola M, Quinn DI, Dorff TB, et al. Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression. Cell Stem Cell. 2014;14:810–23.PubMedPubMedCentralCrossRef
146.
Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, Levesque S, Castoldi F, Jacquelot N, Yamazaki T, et al. Caloric restriction mimetics enhance anticancer immunosurveillance. Cancer Cell. 2016;30:147–60.PubMedPubMedCentralCrossRef
147.
Di Biase S, Lee C, Brandhorst S, Manes B, Buono R, Cheng CW, Cacciottolo M, Martin-Montalvo A, de Cabo R, Wei M, et al. Fasting-mimicking diet reduces HO-1 to promote T cell-mediated tumor cytotoxicity. Cancer Cell. 2016;30:136–46.PubMedPubMedCentralCrossRef
148.
Newman JC, Verdin E. Ketone bodies as signaling metabolites. Trends Endocrinol Metab. 2014;25:42–52.PubMedCrossRef
149.
Di Biase S, Shim HS, Kim KH, Vinciguerra M, Rappa F, Wei M, Brandhorst S, Cappello F, Mirzaei H, Lee C, et al. Fasting regulates EGR1 and protects from glucose- and dexamethasone-dependent sensitization to chemotherapy. PLoS Biol. 2017;15:e2001951.PubMedPubMedCentralCrossRef
150.
Safdie F, Brandhorst S, Wei M, Wang W, Lee C, Hwang S, Conti PS, Chen TC, Longo VD. Fasting enhances the response of glioma to chemo- and radiotherapy. PLoS ONE. 2012;7:e44603.PubMedPubMedCentralCrossRef
151.
Shim HS, Wei M, Brandhorst S, Longo VD. Starvation promotes REV1 SUMOylation and p53-dependent sensitization of melanoma and breast cancer cells. Cancer Res. 2015;75:1056–67.PubMedPubMedCentralCrossRef
152.
Bianchi G, Martella R, Ravera S, Marini C, Capitanio S, Orengo A, Emionite L, Lavarello C, Amaro A, Petretto A, et al. Fasting induces anti-Warburg effect that increases respiration but reduces ATP-synthesis to promote apoptosis in colon cancer models. Oncotarget. 2015;6:11806–19.PubMedPubMedCentralCrossRef
153.
Di Biase S, Longo VD. Fasting-induced differential stress sensitization in cancer treatment. Mol Cell Oncol. 2016;3:e1117701.PubMedCrossRef
154.
Tinkum KL, Stemler KM, White LS, Loza AJ, Jeter-Jones S, Michalski BM, Kuzmicki C, Pless R, Stappenbeck TS, Piwnica-Worms D, et al. Fasting protects mice from lethal DNA damage by promoting small intestinal epithelial stem cell survival. Proc Natl Acad Sci U S A. 2015;112:E7148–54.PubMedPubMedCentralCrossRef
155.
156.
Schumacher B, Garinis GA, Hoeijmakers JH. Age to survive: DNA damage and aging. Trends Genet. 2008;24:77–85.PubMedCrossRef
157.
Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A. 1999;96:7324–9.PubMedPubMedCentralCrossRef
158.
Antunes F, Erustes AG, Costa AJ, Nascimento AC, Bincoletto C, Ureshino RP, Pereira GJS, Smaili SS. Autophagy and intermittent fasting: the connection for cancer therapy? Clinics (Sao Paulo). 2018;73:e814s.CrossRef
159.
Caffa I, Spagnolo V, Vernieri C, Valdemarin F, Becherini P, Wei M, Brandhorst S, Zucal C, Driehuis E, Ferrando L, et al. Fasting-mimicking diet and hormone therapy induce breast cancer regression. Nature. 2020;583:620–4.PubMedPubMedCentralCrossRef
160.
Kanarek N, Petrova B, Sabatini DM. Dietary modifications for enhanced cancer therapy. Nature. 2020;579:507–17.PubMedCrossRef
161.
162.
Brandhorst S, Choi IY, Wei M, Cheng CW, Sedrakyan S, Navarrete G, Dubeau L, Yap LP, Park R, Vinciguerra M, et al. A Periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan. Cell Metab. 2015;22:86–99.PubMedPubMedCentralCrossRef
163.
Lo Re O, Panebianco C, Porto S, Cervi C, Rappa F, Di Biase S, Caraglia M, Pazienza V, Vinciguerra M. Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells. J Cell Physiol. 2018;233:1202–12.PubMedCrossRef
164.
Shi Y, Felley-Bosco E, Marti TM, Orlowski K, Pruschy M, Stahel RA. Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin. BMC Cancer. 2012;12:571.PubMedPubMedCentralCrossRef
165.
Strickaert A, Saiselet M, Dom G, De Deken X, Dumont JE, Feron O, Sonveaux P, Maenhaut C. Cancer heterogeneity is not compatible with one unique cancer cell metabolic map. Oncogene. 2017;36:2637–42.PubMedCrossRef
166.
D’Aronzo M, Vinciguerra M, Mazza T, Panebianco C, Saracino C, Pereira SP, Graziano P, Pazienza V. Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models. Oncotarget. 2015;6:18545–57.PubMedPubMedCentralCrossRef
167.
Lu Z, Xie J, Wu G, Shen J, Collins R, Chen W, Kang X, Luo M, Zou Y, Huang LJ, et al. Fasting selectively blocks development of acute lymphoblastic leukemia via leptin-receptor upregulation. Nat Med. 2017;23:79–90.PubMedCrossRef
168.
Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, et al. Metabolic gatekeeper function of B-lymphoid transcription factors. Nature. 2017;542:479–83.PubMedPubMedCentralCrossRef
169.
Moore SC, Lee IM, Weiderpass E, Campbell PT, Sampson JN, Kitahara CM, Keadle SK, Arem H, Berrington de Gonzalez A, Hartge P, et al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern Med. 2016;176:816–25.PubMedPubMedCentralCrossRef
170.
Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol. 2011;29:726–32.PubMedPubMedCentralCrossRef
171.
172.
Van Blarigan EL, Fuchs CS, Niedzwiecki D, Zhang S, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, et al. Association of survival with adherence to the American Cancer Society nutrition and physical activity guidelines for cancer survivors after colon cancer diagnosis: the CALGB 89803/alliance trial. JAMA Oncol. 2018;4:783–90.PubMedPubMedCentralCrossRef
173.
Cannioto RA, Hutson A, Dighe S, McCann W, McCann SE, Zirpoli GR, Barlow W, Kelly KM, DeNysschen CA, Hershman DL, et al. Physical activity before, during, and after chemotherapy for high-risk breast cancer: relationships with survival. J Natl Cancer Inst. 2021;113:54–63.CrossRefPubMed
174.
Ashcraft KA, Peace RM, Betof AS, Dewhirst MW, Jones LW. Efficacy and mechanisms of aerobic exercise on cancer initiation, progression, and metastasis: a critical systematic review of in vivo preclinical data. Cancer Res. 2016;76:4032–50.PubMedPubMedCentralCrossRef
175.
Koelwyn GJ, Quail DF, Zhang X, White RM, Jones LW. Exercise-dependent regulation of the tumour microenvironment. Nat Rev Cancer. 2017;17:620–32.PubMedCrossRef
176.
Arfianti A, Pok S, Barn V, Haigh WG, Yeh MM, Ioannou GN, Teoh NC, Farrell GC. Exercise retards hepatocarcinogenesis in obese mice independently of weight control. J Hepatol. 2020;73:140–8.PubMedCrossRef
177.
Pedersen L, Christensen JF, Hojman P. Effects of exercise on tumor physiology and metabolism. Cancer J. 2015;21:111–6.PubMedCrossRef
178.
Colbert LH, Westerlind KC, Perkins SN, Haines DC, Berrigan D, Donehower LA, Fuchs-Young R, Hursting SD. Exercise effects on tumorigenesis in a p53-deficient mouse model of breast cancer. Med Sci Sports Exerc. 2009;41:1597–605.PubMedPubMedCentralCrossRef
179.
Gustafson MP, Wheatley-Guy CM, Rosenthal AC, Gastineau DA, Katsanis E, Johnson BD, Simpson RJ. Exercise and the immune system: taking steps to improve responses to cancer immunotherapy. J Immunother Cancer. 2021;9:e001872.PubMedPubMedCentralCrossRef
180.
Idorn M, Hojman P. Exercise-dependent regulation of NK cells in cancer protection. Trends Mol Med. 2016;22:565–77.PubMedCrossRef
181.
Song M, Chan AT. The potential role of exercise and nutrition in harnessing the immune system to improve colorectal cancer survival. Gastroenterology. 2018;155:596–600.PubMedCrossRef
182.
Evans ES, Hackney AC, McMurray RG, Randell SH, Muss HB, Deal AM, Battaglini CL. Impact of acute intermittent exercise on natural killer cells in breast cancer survivors. Integr Cancer Ther. 2015;14:436–45.CrossRefPubMed
183.
Coletta AM, Agha NH, Baker FL, Niemiro GM, Mylabathula PL, Brewster AM, Bevers TB, Fuentes-Mattei E, Basen-Engquist K, Gilchrist SC, et al. The impact of high-intensity interval exercise training on NK-cell function and circulating myokines for breast cancer prevention among women at high risk for breast cancer. Breast Cancer Res Treat. 2021;187:407–16.PubMedPubMedCentralCrossRef
184.
Fisher DT, Chen Q, Skitzki JJ, Muhitch JB, Zhou L, Appenheimer MM, Vardam TD, Weis EL, Passanese J, Wang WC, et al. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest. 2011;121:3846–59.PubMedPubMedCentralCrossRef
185.
Pedersen L, Idorn M, Olofsson GH, Lauenborg B, Nookaew I, Hansen RH, Johannesen HH, Becker JC, Pedersen KS, Dethlefsen C, et al. Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution. Cell Metab. 2016;23:554–62.CrossRefPubMed
186.
Rundqvist H, Velica P, Barbieri L, Gameiro PA, Bargiela D, Gojkovic M, Mijwel S, Reitzner SM, Wulliman D, Ahlstedt E, et al. Cytotoxic T-cells mediate exercise-induced reductions in tumor growth. Elife. 2020;9:e59996.PubMedPubMedCentralCrossRef
187.
Gross E, Sunwoo JB, Bui JD. Cancer immunosurveillance and immunoediting by natural killer cells. Cancer J. 2013;19:483–9.PubMedCrossRef
188.
Bartlett DB, Duggal NA. Moderate physical activity associated with a higher naive/memory T-cell ratio in healthy old individuals: potential role of IL15. Age Ageing. 2020;49:368–73.PubMedCrossRef
189.
Duggal NA, Pollock RD, Lazarus NR, Harridge S, Lord JM. Major features of immunesenescence, including reduced thymic output, are ameliorated by high levels of physical activity in adulthood. Aging Cell. 2018;17:e12750.PubMedCentralCrossRef
190.
191.
Hurwitz MD. Hyperthermia and immunotherapy: clinical opportunities. Int J Hyperthermia. 2019;36:4–9.PubMedCrossRef
192.
Mahmood J, Shukla HD, Soman S, Samanta S, Singh P, Kamlapurkar S, Saeed A, Amin NP, Vujaskovic Z. Immunotherapy, radiotherapy, and hyperthermia: a combined therapeutic approach in pancreatic cancer treatment. Cancers (Basel). 2018;10:469.PubMedCentralCrossRef
193.
Chang M, Hou Z, Wang M, Li C, Lin J. Recent advances in hyperthermia therapy-based synergistic immunotherapy. Adv Mater. 2021;33:e2004788.PubMedCrossRef
194.
195.
Wang J, Liu S, Li G, Xiao J. Exercise regulates the immune system. Adv Exp Med Biol. 2020;1228:395–408.PubMedCrossRef
196.
Scheffer DDL, Latini A. Exercise-induced immune system response: Anti-inflammatory status on peripheral and central organs. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165823.PubMedPubMedCentralCrossRef
197.
Ticinesi A, Lauretani F, Tana C, Nouvenne A, Ridolo E, Meschi T. Exercise and immune system as modulators of intestinal microbiome: implications for the gut-muscle axis hypothesis. Exerc Immunol Rev. 2019;25:84–95.PubMed
198.
Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8:457–65.PubMedCrossRef
199.
Hoffmann C, Weigert C. Skeletal muscle as an endocrine organ: the role of myokines in exercise adaptations. Cold Spring Harb Perspect Med. 2017;7:a029793.PubMedPubMedCentralCrossRef
200.
Ruiz-Casado A, Martin-Ruiz A, Perez LM, Provencio M, Fiuza-Luces C, Lucia A. Exercise and the Hallmarks of Cancer. Trends Cancer. 2017;3:423–41.PubMedCrossRef
201.
202.
Whitham M, Febbraio MA. The ever-expanding myokinome: discovery challenges and therapeutic implications. Nat Rev Drug Discov. 2016;15:719–29.PubMedCrossRef
203.
Catoire M, Mensink M, Kalkhoven E, Schrauwen P, Kersten S. Identification of human exercise-induced myokines using secretome analysis. Physiol Genomics. 2014;46:256–67.PubMedCrossRef
204.
Weigert C, Lehmann R, Hartwig S, Lehr S. The secretome of the working human skeletal muscle—a promising opportunity to combat the metabolic disaster? Proteomics Clin Appl. 2014;8:5–18.PubMedCrossRef
205.
206.
Pourteymour S, Eckardt K, Holen T, Langleite T, Lee S, Jensen J, Birkeland KI, Drevon CA, Hjorth M. Global mRNA sequencing of human skeletal muscle: search for novel exercise-regulated myokines. Mol Metab. 2017;6:352–65.PubMedPubMedCentralCrossRef
207.
Rocha-Rodrigues S, Matos A, Afonso J, Mendes-Ferreira M, Abade E, Teixeira E, Silva B, Murawska-Cialowicz E, Oliveira MJ, Ribeiro R. Skeletal muscle-adipose tissue-tumor axis: molecular mechanisms linking exercise training in prostate cancer. Int J Mol Sci. 2021;22:4469.PubMedPubMedCentralCrossRef
208.
Kim JS, Galvao DA, Newton RU, Gray E, Taaffe DR. Exercise-induced myokines and their effect on prostate cancer. Nat Rev Urol. 2021;18:519–42.PubMedCrossRef
209.
Gannon NP, Vaughan RA, Garcia-Smith R, Bisoffi M, Trujillo KA. Effects of the exercise-inducible myokine irisin on malignant and non-malignant breast epithelial cell behavior in vitro. Int J Cancer. 2015;136:E197-202.PubMedCrossRef
210.
Kim JS, Wilson RL, Taaffe DR, Galvao DA, Gray E, Newton RU. Myokine expression and tumor-suppressive effect of serum following 12 weeks of exercise in prostate cancer patients on ADT. Med Sci Sports Exerc. 2021;54:197–205.PubMedCentralCrossRef
211.
Aoi W, Naito Y, Takagi T, Tanimura Y, Takanami Y, Kawai Y, Sakuma K, Hang LP, Mizushima K, Hirai Y, et al. A novel myokine, secreted protein acidic and rich in cysteine (SPARC), suppresses colon tumorigenesis via regular exercise. Gut. 2013;62:882–9.PubMedCrossRef
212.
Liu YP, Hsiao M. Exercise-induced SPARC prevents tumorigenesis of colon cancer. Gut. 2013;62:810–1.PubMedCrossRef
213.
Matsuo K, Sato K, Suemoto K, Miyamoto-Mikami E, Fuku N, Higashida K, Tsuji K, Xu Y, Liu X, Iemitsu M, et al. A mechanism underlying preventive effect of high-intensity training on colon cancer. Med Sci Sports Exerc. 2017;49:1805–16.PubMedCrossRef
214.
215.
Kim JS, Galvao DA, Newton RU, Gray E, Taaffe DR. Publisher correction: exercise-induced myokines and their effect on prostate cancer. Nat Rev Urol. 2021;19:64.CrossRef
216.
Severinsen MCK, Pedersen BK. Corrigendum to: Muscle-organ crosstalk: the emerging roles of myokines. Endocr Rev. 2021;42:97–9.CrossRef
217.
Li X, Liu Y, Liu Q, Wang S, Ma Y, Jin Q. Recombinant human irisin regulated collagen II, matrix metalloproteinase-13 and the Wnt/beta-catenin and NF-kappaB signaling pathways in interleukin-1beta-induced human SW1353 cells. Exp Ther Med. 2020;19:2879–86.PubMedPubMedCentral
218.
Chen X, Sun K, Zhao S, Geng T, Fan X, Sun S, Zheng M, Jin Q. Irisin promotes osteogenic differentiation of bone marrow mesenchymal stem cells by activating autophagy via the Wnt//beta-catenin signal pathway. Cytokine. 2020;136:155292.PubMedCrossRef
219.
Dong HN, Park SY, Le CT, Choi DH, Cho EH. Irisin regulates the functions of hepatic stellate cells. Endocrinol Metab (Seoul). 2020;35:647–55.CrossRef
220.
221.
Roy P, Chowdhury S, Roy HK. Exercise-induced myokines as emerging therapeutic agents in colorectal cancer prevention and treatment. Future Oncol. 2018;14:309–12.PubMedCrossRef
222.
Khan SU, Ghafoor S. Myokines: discovery challenges and therapeutic impediments. J Pak Med Assoc. 2019;69:1014–7.PubMed
223.
Leal LG, Lopes MA, Batista ML Jr. Physical exercise-induced myokines and muscle-adipose tissue crosstalk: a review of current knowledge and the implications for health and metabolic diseases. Front Physiol. 2018;9:1307.PubMedPubMedCentralCrossRef
224.
Hennigar SR, McClung JP, Pasiakos SM. Nutritional interventions and the IL-6 response to exercise. FASEB J. 2017;31:3719–28.PubMedCrossRef
225.
Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev. 2008;88:1379–406.PubMedCrossRef
226.
Pedersen BK, Febbraio M. Muscle-derived interleukin-6—a possible link between skeletal muscle, adipose tissue, liver, and brain. Brain Behav Immun. 2005;19:371–6.PubMedCrossRef
227.
Tsai MS, Kuo ML, Chang CC, Wu YT. The effects of exercise training on levels of vascular endothelial growth factor in tumor-bearing mice. Cancer Biomark. 2013;13:307–13.PubMedCrossRef
228.
Vital TM, Stein AM, de Melo Coelho FG, Arantes FJ, Teodorov E, Santos-Galduroz RF. Physical exercise and vascular endothelial growth factor (VEGF) in elderly: a systematic review. Arch Gerontol Geriatr. 2014;59:234–9.PubMedCrossRef
229.
Shalamzari SA, Agha-Alinejad H, Alizadeh S, Shahbazi S, Khatib ZK, Kazemi A, Saei MA, Minayi N. The effect of exercise training on the level of tissue IL-6 and vascular endothelial growth factor in breast cancer bearing mice. Iran J Basic Med Sci. 2014;17:231–58.PubMedPubMedCentral
230.
Buss LA, Dachs GU. Effects of exercise on the tumour microenvironment. Adv Exp Med Biol. 2020;1225:31–51.PubMedCrossRef
231.
Buss LA, Ang AD, Hock B, Robinson BA, Currie MJ, Dachs GU. Effect of post-implant exercise on tumour growth rate, perfusion and hypoxia in mice. PLoS ONE. 2020;15:e0229290.PubMedPubMedCentralCrossRef
232.
Betof AS, Lascola CD, Weitzel D, Landon C, Scarbrough PM, Devi GR, Palmer G, Jones LW, Dewhirst MW. Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise. J Natl Cancer Inst. 2015;107:div040.CrossRef
233.
Goel S, Wong AH, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med. 2012;2:a006486.PubMedPubMedCentralCrossRef
234.
Buss LA, Dachs GU. Voluntary exercise slows breast tumor establishment and reduces tumor hypoxia in ApoE(-/-) mice. J Appl Physiol. 1985;2018(124):938–49.
235.
Lin B, Song X, Yang D, Bai D, Yao Y, Lu N. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRbeta and FGFR1. Gene. 2018;654:77–86.PubMedCrossRef
236.
Jones LW, Antonelli J, Masko EM, Broadwater G, Lascola CD, Fels D, Dewhirst MW, Dyck JR, Nagendran J, Flores CT, et al. Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. J Appl Physiol. 1985;2012(113):263–72.
237.
Jones LW, Viglianti BL, Tashjian JA, Kothadia SM, Keir ST, Freedland SJ, Potter MQ, Moon EJ, Schroeder T, Herndon JE 2nd, et al. Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer. J Appl Physiol. 1985;2010(108):343–8.
238.
Patel DI, Abuchowski K, Bedolla R, Rivas P, Musi N, Reddick R, Kumar AP. Nexrutine and exercise similarly prevent high grade prostate tumors in transgenic mouse model. PLoS ONE. 2019;14:e0226187.PubMedPubMedCentralCrossRef
239.
Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood. 2004;104:2224–34.PubMedCrossRef
240.
Murdoch C, Lewis CE. Macrophage migration and gene expression in response to tumor hypoxia. Int J Cancer. 2005;117:701–8.PubMedCrossRef
241.
Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9:1269–74.PubMedCrossRef
242.
Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B, Tobias AL, Han Y, Lesniak MS. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res. 2012;18:6110–21.PubMedPubMedCentralCrossRef
243.
Kiyozumi Y, Baba Y, Okadome K, Yagi T, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe M, Komohara Y, et al. IDO1 expression is associated with immune tolerance and poor prognosis in patients with surgically resected esophageal cancer. Ann Surg. 2019;269:1101–8.PubMedCrossRef
244.
Hatfield SM, Kjaergaard J, Lukashev D, Schreiber TH, Belikoff B, Abbott R, Sethumadhavan S, Philbrook P, Ko K, Cannici R, et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med. 2015;7:277ra30.PubMedPubMedCentralCrossRef
245.
Leone RD, Horton MR, Powell JD. Something in the air: hyperoxic conditioning of the tumor microenvironment for enhanced immunotherapy. Cancer Cell. 2015;27:435–6.PubMedPubMedCentralCrossRef
246.
Barsoum IB, Smallwood CA, Siemens DR, Graham CH. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014;74:665–74.PubMedCrossRef
247.
Barsoum IB, Hamilton TK, Li X, Cotechini T, Miles EA, Siemens DR, Graham CH. Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res. 2011;71:7433–41.PubMedCrossRef
248.
Ruf M, Moch H, Schraml P. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. Int J Cancer. 2016;139:396–403.PubMedCrossRef
249.
Buss LA, Williams T, Hock B, Ang AD, Robinson BA, Currie MJ, Dachs GU. Effects of exercise and anti-PD-1 on the tumour microenvironment. Immunol Lett. 2021;239:60–71.PubMedCrossRef
250.
251.
Dey A, Varelas X, Guan KL. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov. 2020;19:480–94.PubMedPubMedCentralCrossRef
252.
Moya IM, Halder G. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine. Nat Rev Mol Cell Biol. 2019;20:211–26.PubMedCrossRef
253.
254.
255.
Dethlefsen C, Hansen LS, Lillelund C, Andersen C, Gehl J, Christensen JF, Pedersen BK, Hojman P. Exercise-induced catecholamines activate the hippo tumor suppressor pathway to reduce risks of breast cancer development. Cancer Res. 2017;77:4894–904.PubMedCrossRef
256.
Hojman P, Gehl J, Christensen JF, Pedersen BK. Molecular mechanisms linking exercise to cancer prevention and treatment. Cell Metab. 2018;27:10–21.PubMedCrossRef
257.
Hojman P. Exercise protects from cancer through regulation of immune function and inflammation. Biochem Soc Trans. 2017;45:905–11.PubMedCrossRef
258.
Bigley AB, Spielmann G, LaVoy EC, Simpson RJ. Can exercise-related improvements in immunity influence cancer prevention and prognosis in the elderly? Maturitas. 2013;76:51–6.PubMedCrossRef
259.
260.
261.
262.
Takahashi JS. Transcriptional architecture of the mammalian circadian clock. Nat Rev Genet. 2017;18:164–79.PubMedCrossRef
263.
Cho H, Zhao X, Hatori M, Yu RT, Barish GD, Lam MT, Chong LW, DiTacchio L, Atkins AR, Glass CK, et al. Regulation of circadian behaviour and metabolism by REV-ERB-alpha and REV-ERB-beta. Nature. 2012;485:123–7.PubMedPubMedCentralCrossRef
264.
Solt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ, Lundasen T, Shin Y, Liu J, Cameron MD, Noel R, et al. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature. 2012;485:62–8.PubMedPubMedCentralCrossRef
265.
Uriz-Huarte A, Date A, Ang H, Ali S, Brady HJM, Fuchter MJ. The transcriptional repressor REV-ERB as a novel target for disease. Bioorg Med Chem Lett. 2020;30:127395.PubMedCrossRef
266.
267.
Grant D, Yin L, Collins JL, Parks DJ, Orband-Miller LA, Wisely GB, Joshi S, Lazar MA, Willson TM, Zuercher WJ. GSK4112, a small molecule chemical probe for the cell biology of the nuclear heme receptor Rev-erbalpha. ACS Chem Biol. 2010;5:925–32.PubMedCrossRef
268.
Chen H, Chu G, Zhao L, Yamauchi N, Shigeyoshi Y, Hashimoto S, Hattori MA. Rev-erbalpha regulates circadian rhythms and StAR expression in rat granulosa cells as identified by the agonist GSK4112. Biochem Biophys Res Commun. 2012;420:374–9.PubMedCrossRef
269.
Geldof L, Deventer K, Roels K, Tudela E, Van Eeno P. In vitro metabolic studies of REV-ERB Agonists SR9009 and SR9011. Int J Mol Sci. 2016;17:1676.PubMedCentralCrossRef
270.
Mazzarino M, Rizzato N, Stacchini C, de la Torre X, Botre F. A further insight into the metabolic profile of the nuclear receptor Rev-erb agonist, SR9009. Drug Test Anal. 2018;10:1670–81.PubMedCrossRef
271.
Wagner PM, Monjes NM, Guido ME. Chemotherapeutic effect of SR9009, a REV-ERB agonist, on the human glioblastoma T98G cells. ASN Neuro. 2019;11:1759091419892713.PubMedPubMedCentralCrossRef
272.
Wang Y, Kojetin D, Burris TP. Anti-proliferative actions of a synthetic REV-ERBalpha/beta agonist in breast cancer cells. Biochem Pharmacol. 2015;96:315–22.PubMedPubMedCentralCrossRef
273.
Shen W, Zhang W, Ye W, Wang H, Zhang Q, Shen J, Hong Q, Li X, Wen G, Wei T, et al. SR9009 induces a REV-ERB dependent anti-small-cell lung cancer effect through inhibition of autophagy. Theranostics. 2020;10:4466–80.PubMedPubMedCentralCrossRef
274.
Sulli G, Rommel A, Wang X, Kolar MJ, Puca F, Saghatelian A, Plikus MV, Verma IM, Panda S. Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Nature. 2018;553:351–5.PubMedPubMedCentralCrossRef
275.
Dong Z, Zhang G, Qu M, Gimple RC, Wu Q, Qiu Z, Prager BC, Wang X, Kim LJY, Morton AR, et al. Targeting glioblastoma stem cells through disruption of the circadian clock. Cancer Discov. 2019;9:1556–73.PubMedPubMedCentralCrossRef
276.
Trump RP, Bresciani S, Cooper AW, Tellam JP, Wojno J, Blaikley J, Orband-Miller LA, Kashatus JA, Boudjelal M, Dawson HC, et al. Optimized chemical probes for REV-ERBalpha. J Med Chem. 2013;56:4729–37.PubMedPubMedCentralCrossRef
277.
Guillaumond F, Dardente H, Giguere V, Cermakian N. Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors. J Biol Rhythms. 2005;20:391–403.PubMedCrossRef
278.
Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, et al. ROR-gamma drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med. 2016;22:488–96.PubMedPubMedCentralCrossRef
279.
Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, et al. Corrigendum: ROR-gamma drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med. 2016;22:692.PubMedPubMedCentralCrossRef
280.
Stone L. Prostate cancer: ROR-gamma drives androgen receptor expression. Nat Rev Urol. 2016;13:237.PubMedCrossRef
281.
Zheng J, Wang J, Wang Q, Zou H, Wang H, Zhang Z, Chen J, Wang Q, Wang P, Zhao Y, et al. Targeting castration-resistant prostate cancer with a novel RORgamma antagonist elaiophylin. Acta Pharm Sin B. 2020;10:2313–22.PubMedPubMedCentralCrossRef
282.
Gao M, Guo L, Wang H, Huang J, Han F, Xiang S, Wang J. Orphan nuclear receptor RORgamma confers doxorubicin resistance in prostate cancer. Cell Biol Int. 2020;44:2170–6.PubMedCrossRef
283.
Lytle NK, Ferguson LP, Rajbhandari N, Gilroy K, Fox RG, Deshpande A, Schurch CM, Hamilton M, Robertson N, Lin W, et al. A multiscale map of the stem cell state in pancreatic adenocarcinoma. Cell. 2019;177:572-86.e22.PubMedPubMedCentralCrossRef
284.
285.
Jetten AM, Cook DN. (Inverse) Agonists of retinoic acid-related orphan receptor gamma: regulation of immune responses, inflammation, and autoimmune disease. Annu Rev Pharmacol Toxicol. 2020;60:371–90.PubMedCrossRef
286.
Liu X, Zawidzka EM, Li H, Lesch CA, Dunbar J, Bousley D, Zou W, Hu X, Carter LL. RORgamma agonists enhance the sustained antitumor activity through intrinsic Tc17 cytotoxicity and Tc1 recruitment. Cancer Immunol Res. 2019;7:1054–63.PubMedCrossRef
287.
Chang MR, Dharmarajan V, Doebelin C, Garcia-Ordonez RD, Novick SJ, Kuruvilla DS, Kamenecka TM, Griffin PR. Synthetic RORgammat agonists enhance protective immunity. ACS Chem Biol. 2016;11:1012–8.PubMedPubMedCentralCrossRef
288.
Hu X, Liu X, Moisan J, Wang Y, Lesch CA, Spooner C, Morgan RW, Zawidzka EM, Mertz D, Bousley D, et al. Synthetic RORgamma agonists regulate multiple pathways to enhance antitumor immunity. Oncoimmunology. 2016;5:e1254854.PubMedPubMedCentralCrossRef
289.
Mahalingam D, Wang JS, Hamilton EP, Sarantopoulos J, Nemunaitis J, Weems G, Carter L, Hu X, Schreeder M, Wilkins HJ. Phase 1 open-label, multicenter study of first-in-class RORgamma agonist LYC-55716 (cintirorgon): safety, tolerability, and preliminary evidence of antitumor activity. Clin Cancer Res. 2019;25:3508–16.PubMedCrossRef
290.
Zhu Y, McAvoy S, Kuhn R, Smith DI. RORA, a large common fragile site gene, is involved in cellular stress response. Oncogene. 2006;25:2901–8.PubMedCrossRef
291.
Mao W, Xiong G, Wu Y, Wang C, St Clair D, Li JD, Xu R. RORalpha suppresses cancer-associated inflammation by repressing respiratory complex I-dependent ROS generation. Int J Mol Sci. 2021;22:10665.PubMedPubMedCentralCrossRef
292.
Park SC, Park IG, Kim H, Lee JM. N-terminal domain mediated regulation of RORalpha1 inhibits invasive growth in prostate cancer. Int J Mol Sci. 2019;20:1684.PubMedCentralCrossRef
293.
Wang Z, Xiong F, Wang X, Qi Y, Yu H, Zhu Y, Zhu H. Nuclear receptor retinoid-related orphan receptor alpha promotes apoptosis but is reduced in human gastric cancer. Oncotarget. 2017;8:11105–13.PubMedCrossRef
294.
295.
Wang Y, Kumar N, Nuhant P, Cameron MD, Istrate MA, Roush WR, Griffin PR, Burris TP. Identification of SR1078, a synthetic agonist for the orphan nuclear receptors RORalpha and RORgamma. ACS Chem Biol. 2010;5:1029–34.PubMedPubMedCentralCrossRef
296.
Zhang S, Zhang J, Deng Z, Liu H, Mao W, Jiang F, Xia Z, Li JD. Circadian clock components RORalpha and Bmal1 mediate the anti-proliferative effect of MLN4924 in osteosarcoma cells. Oncotarget. 2016;7:66087–99.PubMedPubMedCentralCrossRef
297.
Zhang Y, Shi CC, Zhang HP, Li GQ, Li SS. MLN4924 suppresses neddylation and induces cell cycle arrest, senescence, and apoptosis in human osteosarcoma. Oncotarget. 2016;7:45263–74.PubMedPubMedCentralCrossRef
298.
Wu MH, Lee CY, Huang TJ, Huang KY, Tang CH, Liu SH, Kuo KL, Kuan FC, Lin WC, Shi CS. MLN4924, a protein neddylation inhibitor, suppresses the growth of human chondrosarcoma through inhibiting cell proliferation and inducing endoplasmic reticulum stress-related apoptosis. Int J Mol Sci. 2018;20:72.PubMedCentralCrossRef
299.
Han K, Wang Q, Cao H, Qiu G, Cao J, Li X, Wang J, Shen B, Zhang J. The NEDD8-activating enzyme inhibitor MLN4924 induces G2 arrest and apoptosis in T-cell acute lymphoblastic leukemia. Oncotarget. 2016;7:23812–24.PubMedPubMedCentralCrossRef
300.
Rahman S, Wittine K, Sedic M, Markova-Car EP. Small molecules targeting biological clock; a novel prospective for anti-cancer drugs. Molecules. 2020;25:4937.PubMedCentralCrossRef
301.
Cao X, Yang Y, Selby CP, Liu Z, Sancar A. Molecular mechanism of the repressive phase of the mammalian circadian clock. Proc Natl Acad Sci U S A. 2021;118:e2021174118.PubMedCrossRef
302.
Ye R, Selby CP, Chiou YY, Ozkan-Dagliyan I, Gaddameedhi S, Sancar A. Dual modes of CLOCK:BMAL1 inhibition mediated by cryptochrome and period proteins in the mammalian circadian clock. Genes Dev. 2014;28:1989–98.PubMedPubMedCentralCrossRef
303.
Chiou YY, Yang Y, Rashid N, Ye R, Selby CP, Sancar A. Mammalian period represses and de-represses transcription by displacing CLOCK-BMAL1 from promoters in a Cryptochrome-dependent manner. Proc Natl Acad Sci U S A. 2016;113:E6072–9.PubMedPubMedCentralCrossRef
304.
Parico GCG, Perez I, Fribourgh JL, Hernandez BN, Lee HW, Partch CL. The human CRY1 tail controls circadian timing by regulating its association with CLOCK:BMAL1. Proc Natl Acad Sci U S A. 2020;117:27971–9.PubMedPubMedCentralCrossRef
305.
Hirota T, Lee JW, St John PC, Sawa M, Iwaisako K, Noguchi T, Pongsawakul PY, Sonntag T, Welsh DK, Brenner DA, et al. Identification of small molecule activators of cryptochrome. Science. 2012;337:1094–7.PubMedPubMedCentralCrossRef
306.
Solanas G, Benitah SA. Alterations to the circadian clock make brain tumours vulnerable. Nature. 2019;574:337–8.PubMedCrossRef
307.
Chun SK, Chung S, Kim HD, Lee JH, Jang J, Kim J, Kim D, Son GH, Oh YJ, Suh YG, et al. A synthetic cryptochrome inhibitor induces anti-proliferative effects and increases chemosensitivity in human breast cancer cells. Biochem Biophys Res Commun. 2015;467:441–6.PubMedCrossRef
308.
Eide EJ, Woolf MF, Kang H, Woolf P, Hurst W, Camacho F, Vielhaber EL, Giovanni A, Virshup DM. Control of mammalian circadian rhythm by CKIepsilon-regulated proteasome-mediated PER2 degradation. Mol Cell Biol. 2005;25:2795–807.PubMedPubMedCentralCrossRef
309.
Isojima Y, Nakajima M, Ukai H, Fujishima H, Yamada RG, Masumoto KH, Kiuchi R, Ishida M, Ukai-Tadenuma M, Minami Y, et al. CKIepsilon/delta-dependent phosphorylation is a temperature-insensitive, period-determining process in the mammalian circadian clock. Proc Natl Acad Sci U S A. 2009;106:15744–9.PubMedPubMedCentralCrossRef
310.
Yang Y, Xu T, Zhang Y, Qin X. Molecular basis for the regulation of the circadian clock kinases CK1delta and CK1epsilon. Cell Signal. 2017;31:58–65.PubMedCrossRef
311.
Guo G, Wang K, Hu SS, Tian T, Liu P, Mori T, Chen P, Johnson CH, Qin X. Autokinase activity of casein kinase 1 delta/epsilon governs the period of mammalian circadian rhythms. J Biol Rhythms. 2019;34:482–96.PubMedPubMedCentralCrossRef
312.
Janovska P, Normant E, Miskin H, Bryja V. Targeting casein kinase 1 (CK1) in hematological cancers. Int J Mol Sci. 2020;21:9026.PubMedCentralCrossRef
313.
Sinnberg T, Wang J, Sauer B, Schittek B. Casein kinase 1alpha has a non-redundant and dominant role within the CK1 family in melanoma progression. BMC Cancer. 2016;16:594.PubMedPubMedCentralCrossRef
314.
Rosenberg LH, Lafitte M, Quereda V, Grant W, Chen W, Bibian M, Noguchi Y, Fallahi M, Yang C, Chang JC, et al. Therapeutic targeting of casein kinase 1delta in breast cancer. Sci Transl Med. 2015;7:318ra202.PubMedPubMedCentralCrossRef
315.
Shen C, Nayak A, Melendez RA, Wynn DT, Jackson J, Lee E, Ahmed Y, Robbins DJ. Casein kinase 1alpha as a regulator of Wnt-driven cancer. Int J Mol Sci. 2020;21:5940.PubMedCentralCrossRef
316.
Bibian M, Rahaim RJ, Choi JY, Noguchi Y, Schurer S, Chen W, Nakanishi S, Licht K, Rosenberg LH, Li L, et al. Development of highly selective casein kinase 1delta/1epsilon (CK1delta/epsilon) inhibitors with potent antiproliferative properties. Bioorg Med Chem Lett. 2013;23:4374–80.PubMedPubMedCentralCrossRef
317.
Minzel W, Venkatachalam A, Fink A, Hung E, Brachya G, Burstain I, Shaham M, Rivlin A, Omer I, Zinger A, et al. Small molecules co-targeting CKIalpha and the transcriptional kinases CDK7/9 control AML in preclinical models. Cell. 2018;175:171–85.PubMedPubMedCentralCrossRef
318.
Hanif IM, Hanif IM, Shazib MA, Ahmad KA, Pervaiz S. Casein kinase II: an attractive target for anti-cancer drug design. Int J Biochem Cell Biol. 2010;42:1602–5.PubMedCrossRef
319.
Kim HJ, Han YS, Lee JH, Lee SH. Casein Kinase 2alpha Enhances 5-fluorouracil resistance in colorectal cancer cells by inhibiting endoplasmic reticulum stress. Anticancer Res. 2020;40:1419–26.PubMedCrossRef
320.
Hashimoto A, Gao C, Mastio J, Kossenkov A, Abrams SI, Purandare AV, Desilva H, Wee S, Hunt J, Jure-Kunkel M, et al. Inhibition of casein kinase 2 disrupts differentiation of myeloid cells in cancer and enhances the efficacy of immunotherapy in mice. Cancer Res. 2018;78:5644–55.PubMedPubMedCentralCrossRef
321.
Kim HM, Jeong I, Kim HJ, Kang SK, Kwon WS, Kim TS, Park KH, Jung M, Soong J, Lin SC, et al. Casein kinase 2 inhibitor, CX-4945, as a potential targeted anticancer agent in gastric cancer. Anticancer Res. 2018;38:6171–80.PubMedCrossRef
322.
Oshima T, Niwa Y, Kuwata K, Srivastava A, Hyoda T, Tsuchiya Y, Kumagai M, Tsuyuguchi M, Tamaru T, Sugiyama A, et al. Cell-based screen identifies a new potent and highly selective CK2 inhibitor for modulation of circadian rhythms and cancer cell growth. Sci Adv. 2019;5:eaau9060.PubMedPubMedCentralCrossRef
323.
Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O’Brien SE, Bliesath J, Omori M, Huser N, Ho C, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010;70:10288–98.PubMedCrossRef
324.
D’Amore C, Borgo C, Sarno S, Salvi M. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy—potential clinical relevance. Cell Oncol (Dordr). 2020;43:1003–16.CrossRef
325.
Pierre F, Chua PC, O’Brien SE, Siddiqui-Jain A, Bourbon P, Haddach M, Michaux J, Nagasawa J, Schwaebe MK, Stefan E, et al. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Mol Cell Biochem. 2011;356:37–43.PubMedCrossRef
326.
327.
Yang Y, Lindsey-Boltz LA, Vaughn CM, Selby CP, Cao X, Liu Z, Hsu DS, Sancar A. Circadian clock, carcinogenesis, chronochemotherapy connections. J Biol Chem. 2021;297:101068.PubMedPubMedCentralCrossRef
328.
329.
Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Int Organ Cancer Chronother Lancet. 1997;350:681–6.
330.
Sandor V. Chronotherapy with 5-fluorouracil, oxaliplatin, and folinic acid in colorectal cancer. Lancet. 1997;350:1325–6.PubMedCrossRef
331.
Efficace F, Innominato PF, Bjarnason G, Coens C, Humblet Y, Tumolo S, Genet D, Tampellini M, Bottomley A, Garufi C, et al. Validation of patient’s self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2008;26:2020–6.PubMedCrossRef
332.
Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol. 2006;24:3562–9.PubMedCrossRef
333.
Dong D, Yang D, Lin L, Wang S, Wu B. Circadian rhythm in pharmacokinetics and its relevance to chronotherapy. Biochem Pharmacol. 2020;178:114045.PubMedCrossRef
334.
Hill RJW, Innominato PF, Levi F, Ballesta A. Optimizing circadian drug infusion schedules towards personalized cancer chronotherapy. PLoS Comput Biol. 2020;16:e1007218.PubMedPubMedCentralCrossRef
335.
Bicker J, Alves G, Falcao A, Fortuna A. Timing in drug absorption and disposition: the past, present, and future of chronopharmacokinetics. Br J Pharmacol. 2020;177:2215–39.PubMedPubMedCentralCrossRef
336.
Levi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol. 2010;50:377–421.PubMedCrossRef
337.
Innominato PF, Roche VP, Palesh OG, Ulusakarya A, Spiegel D, Levi FA. The circadian timing system in clinical oncology. Ann Med. 2014;46:191–207.PubMedCrossRef
338.
Dallmann R, Okyar A, Levi F. Dosing-time makes the poison: circadian regulation and pharmacotherapy. Trends Mol Med. 2016;22:430–45.PubMedCrossRef
339.
Levi F, Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol. 2007;47:593–628.PubMedCrossRef
340.
Altinok A, Levi F, Goldbeter A. Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling. Eur J Pharm Sci. 2009;36:20–38.PubMedCrossRef
341.
Binkhorst L, Kloth JSL, de Wit AS, de Bruijn P, Lam MH, Chaves I, Burger H, van Alphen RJ, Hamberg P, van Schaik RHN, et al. Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients. Breast Cancer Res Treat. 2015;152:119–28.PubMedPubMedCentralCrossRef
342.
Kloth JS, Binkhorst L, de Wit AS, de Bruijn P, Hamberg P, Lam MH, Burger H, Chaves I, Wiemer EA, van der Horst GT, et al. Relationship between sunitinib pharmacokinetics and administration time: preclinical and clinical evidence. Clin Pharmacokinet. 2015;54:851–8.PubMedPubMedCentralCrossRef
343.
Lankheet NA, Kloth JS, Gadellaa-van Hooijdonk CG, Cirkel GA, Mathijssen RH, Lolkema MP, Schellens JH, Voest EE, Sleijfer S, de Jonge MJ, et al. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. Br J Cancer. 2014;110:2441–9.PubMedPubMedCentralCrossRef
344.
Liu J, Wang CY, Ji SG, Xu X, Wang PP, Zhang B, Zhao LY, Liu L, Lin PP, Liu LK, et al. chronopharmacokinetics of erlotinib and circadian rhythms of related metabolic enzymes in Lewis tumor-bearing mice. Eur J Drug Metab Pharmacokinet. 2016;41:627–35.PubMedCrossRef
345.
Bajetta E, Pietrantonio F, Buzzoni R, Ferrario E, Valvo F, Mariani L, Dotti KF, Biondani P, Formisano B, Gevorgyan A, et al. Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study. Am J Clin Oncol. 2014;37:545–9.PubMedCrossRef
346.
Akgun Z, Saglam S, Yucel S, Gural Z, Balik E, Cipe G, Yildiz S, Kilickap S, Okyar A, Kaytan-Saglam E. Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study. Cancer Chemother Pharmacol. 2014;74:751–6.PubMedCrossRef
347.
Bernard S, Cajavec Bernard B, Levi F, Herzel H. Tumor growth rate determines the timing of optimal chronomodulated treatment schedules. PLoS Comput Biol. 2010;6:e1000712.PubMedPubMedCentralCrossRef
348.
Hesse J, Martinelli J, Aboumanify O, Ballesta A, Relogio A. A mathematical model of the circadian clock and drug pharmacology to optimize irinotecan administration timing in colorectal cancer. Comput Struct Biotechnol J. 2021;19:5170–83.PubMedPubMedCentralCrossRef
349.
Dulong S, Ballesta A, Okyar A, Levi F. Identification of circadian determinants of cancer chronotherapy through in vitro chronopharmacology and mathematical modeling. Mol Cancer Ther. 2015;14:2154–64.PubMedCrossRef
350.
Ortiz-Tudela E, Iurisci I, Beau J, Karaboue A, Moreau T, Rol MA, Madrid JA, Levi F, Innominato PF. The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy. Int J Cancer. 2014;134:2717–25.PubMedCrossRef
351.
Innominato PF, Karaboue A, Focan C, Chollet P, Giacchetti S, Bouchahda M, Ulusakarya A, Torsello A, Adam R, Levi FA, et al. Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5-fluorouracil and leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: results from the International EORTC 05011 Trial. Int J Cancer. 2020;148:2512–21.PubMedCentralCrossRef
352.
Qian DC, Kleber T, Brammer B, Xu KM, Switchenko JM, Janopaul-Naylor JR, Zhong J, Yushak ML, Harvey RD, Paulos CM, et al. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. Lancet Oncol. 2021;22:1777–86.PubMedCrossRef
353.
Levi F. Daytime versus evening infusions of immune checkpoint inhibitors. Lancet Oncol. 2021;22:1648–50.PubMedCrossRef
354.
Khan Z, Pillay V, Choonara YE, du Toit LC. Drug delivery technologies for chronotherapeutic applications. Pharm Dev Technol. 2009;14:602–12.PubMedCrossRef
355.
Levi F, Okyar A. Circadian clocks and drug delivery systems: impact and opportunities in chronotherapeutics. Expert Opin Drug Deliv. 2011;8:1535–41.PubMedCrossRef
356.
Sunil SA, Srikanth MV, Rao NS, Uhumwangho MU, Latha K, Murthy KV. Chronotherapeutic drug delivery systems: an approach to circadian rhythms diseases. Curr Drug Deliv. 2011;8:622–33.PubMedCrossRef
357.
Popov I, Jelic S, Radosavljevic D. Nikolic-Tomasevic A [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma]. Srp Arh Celok Lek. 1998;126:355–61.PubMed
358.
Focan C, Denis B, Kreutz F, Focan-Henrard D, Levi F. Ambulatory chronotherapy with 5-fluorouracil, folinic acid, and carboplatin for advanced non-small cell lung cancer. A phase II feasibility trial. J Infus Chemother. 1995;5:148–52.PubMed
359.
Levi FA, Boige V, Hebbar M, Smith D, Lepere C, Focan C, Karaboue A, Guimbaud R, Carvalho C, Tumolo S, et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol. 2016;27:267–74.PubMedCrossRef
360.
Bouchahda M, Adam R, Giacchetti S, Castaing D, Brezault-Bonnet C, Hauteville D, Innominato PF, Focan C, Machover D, Levi F. Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer. 2009;115:4990–9.PubMedCrossRef
361.
Levi F, Karaboue A, Etienne-Grimaldi MC, Paintaud G, Focan C, Innominato P, Bouchahda M, Milano G, Chatelut E. Pharmacokinetics of irinotecan, oxaliplatin and 5-fluorouracil during hepatic artery chronomodulated infusion: a translational European OPTILIV Study. Clin Pharmacokinet. 2017;56:165–77.PubMedCrossRef
362.
363.
Ohdo S. Chrono-drug-delivery focused on biological clock: intra- and inter-individual variability of molecular clock. Adv Drug Deliv Rev. 2010;62:857–8.PubMedCrossRef
364.
Zhang Z, Qin S, Chen Y, Zhou L, Yang M, Tang Y, Zuo J, Zhang J, Mizokami A, Nice EC, et al. Inhibition of NPC1L1 disrupts adaptive responses of drug-tolerant persister cells to chemotherapy. EMBO Mol Med. 2022;14:e14903.PubMedPubMedCentralCrossRef
365.
Patil SS, Shahiwala A. Patented pulsatile drug delivery technologies for chronotherapy. Expert Opin Ther Pat. 2014;24:845–56.PubMedCrossRef
366.
Dumpa NR, Sarabu S, Bandari S, Zhang F, Repka MA. Chronotherapeutic drug delivery of ketoprofen and ibuprofen for improved treatment of early morning stiffness in arthritis using hot-melt extrusion technology. AAPS PharmSciTech. 2018;19:2700–9.PubMedCrossRef
367.
Maqbool I, Akhtar M, Ahmad R, Sadaquat H, Noreen S, Batool A, Khan SU. Novel multiparticulate pH triggered delayed release chronotherapeutic drug delivery of celecoxib-beta-cyclodextrin inclusion complexes by using Box–Behnken design. Eur J Pharm Sci. 2020;146:105254.PubMedCrossRef
368.
Hu J, Fu S, Peng Q, Han Y, Xie J, Zan N, Chen Y, Fan J. Paclitaxel-loaded polymeric nanoparticles combined with chronomodulated chemotherapy on lung cancer: in vitro and in vivo evaluation. Int J Pharm. 2017;516:313–22.PubMedCrossRef
369.
Hu J, Fu S, Peng Q, Han Y, Xie J, Zan N, Chen Y, Fan J. Corrigendum to “Paclitaxel-loaded polymeric nanoparticles combined with chronomodulated chemotherapy on lung cancer: in vitro and in vivo evaluation” [Int. J. Pharmaceut. 516 (2017) 313-322]. Int J Pharm. 2020;573:118878.PubMedCrossRef
370.
Zhao X, Fan J, Wu P, Wei C, Chen Q, Ming Z, Yan J, Yang L. Chronic chemotherapy with paclitaxel nanoparticles induced apoptosis in lung cancer in vitro and in vivo. Int J Nanomed. 2019;14:1299–309.CrossRef
371.
372.
373.
Manoogian ENC, Panda S. Circadian rhythms, time-restricted feeding, and healthy aging. Ageing Res Rev. 2017;39:59–67.PubMedCrossRef
374.
Parr EB, Heilbronn LK, Hawley JA. A time to eat and a time to exercise. Exerc Sport Sci Rev. 2020;48:4–10.PubMedCrossRef
375.
376.
Chaix A, Manoogian ENC, Melkani GC, Panda S. Time-restricted eating to prevent and manage chronic metabolic diseases. Annu Rev Nutr. 2019;39:291–315.PubMedPubMedCentralCrossRef
377.
378.
379.
Castejon M, Plaza A, Martinez-Romero J, Fernandez-Marcos PJ, Cabo R, Diaz-Ruiz A. Energy restriction and colorectal cancer: a call for additional research. Nutrients. 2020;12:114.PubMedCentralCrossRef
380.
381.
Sadeghian M, Rahmani S, Khalesi S, Hejazi E. A review of fasting effects on the response of cancer to chemotherapy. Clin Nutr. 2021;40:1669–81.PubMedCrossRef
382.
Wei M, Brandhorst S, Shelehchi M, Mirzaei H, Cheng CW, Budniak J, Groshen S, Mack WJ, Guen E, Di Biase S, et al. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci Transl Med. 2017;9:eaai8700.PubMedPubMedCentralCrossRef
383.
Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, Cohen P, Longo VD. Fasting and cancer treatment in humans: a case series report. Aging (Albany N Y). 2009;1:988–1007.
384.
de Groot S, Vreeswijk MP, Welters MJ, Gravesteijn G, Boei JJ, Jochems A, Houtsma D, Putter H, van der Hoeven JJ, Nortier JW, et al. The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. BMC Cancer. 2015;15:652.PubMedPubMedCentralCrossRef
385.
Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, Cheng CW, Brandhorst S, Cohen P, Wei M, et al. Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer. 2016;16:360.PubMedPubMedCentralCrossRef
386.
Bauersfeld SP, Kessler CS, Wischnewsky M, Jaensch A, Steckhan N, Stange R, Kunz B, Bruckner B, Sehouli J, Michalsen A. The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study. BMC Cancer. 2018;18:476.PubMedPubMedCentralCrossRef
387.
Tahara Y, Aoyama S, Shibata S. The mammalian circadian clock and its entrainment by stress and exercise. J Physiol Sci. 2017;67:1–10.PubMedCrossRef
388.
Sato S, Basse AL, Schonke M, Chen S, Samad M, Altintas A, Laker RC, Dalbram E, Barres R, Baldi P, et al. Time of exercise specifies the impact on muscle metabolic pathways and systemic energy homeostasis. Cell Metab. 2019;30:92-110.e4.PubMedCrossRef
389.
Choi Y, Cho J, No MH, Heo JW, Cho EJ, Chang E, Park DH, Kang JH, Kwak HB. Re-setting the circadian clock using exercise against sarcopenia. Int J Mol Sci. 2020;21:3106.PubMedCentralCrossRef
390.
Garcia-Ortiz L, Recio-Rodriguez JI, Martin-Cantera C, Cabrejas-Sanchez A, Gomez-Arranz A, Gonzalez-Viejo N, Iturregui-San Nicolas E, Patino-Alonso MC, Gomez-Marcos MA, Group E. Physical exercise, fitness and dietary pattern and their relationship with circadian blood pressure pattern, augmentation index and endothelial dysfunction biological markers: EVIDENT study protocol. BMC Public Health. 2010;10:233.PubMedPubMedCentralCrossRef
391.
Matteucci E, Consani C, Masoni MC, Giampietro O. Circadian blood pressure variability in type 1 diabetes subjects and their nondiabetic siblings—influence of erythrocyte electron transfer. Cardiovasc Diabetol. 2010;9:61.PubMedPubMedCentralCrossRef
392.
Chen HM, Cheung DST, Lin YY, Wu YC, Liu CY, Lin KC, Lin YJ, Lin CC. Relationships of exercise timing with sleep, fatigue and rest-activity rhythms of lung cancer patients in Taiwan: an exploratory study. Eur J Cancer Care (Engl). 2020;29:e13233.CrossRef
393.
Gabriel BM, Zierath JR. Circadian rhythms and exercise—re-setting the clock in metabolic disease. Nat Rev Endocrinol. 2019;15:197–206.PubMedCrossRef
394.
Yamanaka Y, Hashimoto S, Takasu NN, Tanahashi Y, Nishide SY, Honma S, Honma K. Morning and evening physical exercise differentially regulate the autonomic nervous system during nocturnal sleep in humans. Am J Physiol Regul Integr Comp Physiol. 2015;309:R1112–21.PubMedCrossRef
395.
Tong CKW, Lau B, Davis MK. Exercise training for cancer survivors. Curr Treat Options Oncol. 2020;21:53.PubMedCrossRef
396.
Cavalheri V, Granger CL. Exercise training as part of lung cancer therapy. Respirology. 2020;25(Suppl 2):80–7.PubMedCrossRef
397.
Cavalheri V, Tahirah F, Nonoyama M, Jenkins S, Hill K. Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer. Cochrane Database Syst Rev. 2013;6:CD009955.
398.
399.
Holmen Olofsson G, Jensen AWP, Idorn M, Thor Straten P. Exercise oncology and immuno-oncology; a (future) dynamic duo. Int J Mol Sci. 2020;21:3816.PubMedCentralCrossRef
400.
Saner NJ, Lee MJ, Kuang J, Pitchford NW, Roach GD, Garnham A, Genders AJ, Stokes T, Schroder EA, Huo Z, et al. Exercise mitigates sleep-loss-induced changes in glucose tolerance, mitochondrial function, sarcoplasmic protein synthesis, and diurnal rhythms. Mol Metab. 2021;43:101110.PubMedCrossRef
401.
Wyld L, Audisio RA, Poston GJ. The evolution of cancer surgery and future perspectives. Nat Rev Clin Oncol. 2015;12:115–24.PubMedCrossRef
402.
Wilson DJ. Exercise for the patient after breast cancer surgery. Semin Oncol Nurs. 2017;33:98–105.PubMedCrossRef
403.
Avancini A, Sartori G, Gkountakos A, Casali M, Trestini I, Tregnago D, Bria E, Jones LW, Milella M, Lanza M, et al. Physical activity and exercise in lung cancer care: will promises be fulfilled? Oncologist. 2020;25:e555–69.PubMedCrossRef
404.
Bourke L, Smith D, Steed L, Hooper R, Carter A, Catto J, Albertsen PC, Tombal B, Payne HA, Rosario DJ. Exercise for men with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69:693–703.CrossRefPubMed
405.
Yang A, Sokolof J, Gulati A. The effect of preoperative exercise on upper extremity recovery following breast cancer surgery: a systematic review. Int J Rehabil Res. 2018;41:189–96.PubMedCrossRef
406.
Rosero ID, Ramirez-Velez R, Lucia A, Martinez-Velilla N, Santos-Lozano A, Valenzuela PL, Morilla I, Izquierdo M. Systematic review and meta-analysis of randomized, controlled trials on preoperative physical exercise interventions in patients with non-small-cell lung cancer. Cancers (Basel). 2019;11:944.PubMedCentralCrossRef
407.
Cavalheri V, Granger C. Preoperative exercise training for patients with non-small cell lung cancer. Cochrane Database Syst Rev. 2017;6:CD012020.PubMed
408.
Ni HJ, Pudasaini B, Yuan XT, Li HF, Shi L, Yuan P. Exercise training for patients pre- and postsurgically treated for non-small cell lung cancer: a systematic review and meta-analysis. Integr Cancer Ther. 2017;16:63–73.PubMedCrossRef
409.
Cavalheri V, Tahirah F, Nonoyama M, Jenkins S, Hill K. Exercise training for people following lung resection for non-small cell lung cancer—a Cochrane systematic review. Cancer Treat Rev. 2014;40:585–94.PubMedCrossRef
410.
Kilgour RD, Jones DH, Keyserlingk JR. Effectiveness of a self-administered, home-based exercise rehabilitation program for women following a modified radical mastectomy and axillary node dissection: a preliminary study. Breast Cancer Res Treat. 2008;109:285–95.PubMedCrossRef
411.
Scaffidi M, Vulpiani MC, Vetrano M, Conforti F, Marchetti MR, Bonifacino A, Marchetti P, Saraceni VM, Ferretti A. Early rehabilitation reduces the onset of complications in the upper limb following breast cancer surgery. Eur J Phys Rehabil Med. 2012;48:601–11.PubMed
412.
Cavalheri V, Burtin C, Formico VR, Nonoyama ML, Jenkins S, Spruit MA, Hill K. Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer. Cochrane Database Syst Rev. 2019;6:CD009955.PubMed
413.
Allen C, Her S, Jaffray DA. Radiotherapy for cancer: present and future. Adv Drug Deliv Rev. 2017;109:1–2.PubMedCrossRef
414.
415.
Schumacher O, Galvao DA, Taaffe DR, Chee R, Spry N, Newton RU. Exercise modulation of tumour perfusion and hypoxia to improve radiotherapy response in prostate cancer. Prostate Cancer Prostatic Dis. 2021;24:1–14.PubMedCrossRef
416.
Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud’Homme DG, Malone SC, Wells GA, Scott CG, Slovinec D’Angelo ME. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol. 2009;27:344–51.PubMedCrossRef
417.
Lipsett A, Barrett S, Haruna F, Mustian K, O’Donovan A. The impact of exercise during adjuvant radiotherapy for breast cancer on fatigue and quality of life: a systematic review and meta-analysis. Breast. 2017;32:144–55.CrossRefPubMed
418.
Kapur G, Windsor PM, McCowan C. The effect of aerobic exercise on treatment-related acute toxicity in men receiving radical external beam radiotherapy for localised prostate cancer. Eur J Cancer Care (Engl). 2010;19:643–7.CrossRef
419.
Dufresne S, Gueritat J, Chiavassa S, Noblet C, Assi M, Rioux-Leclercq N, Rannou-Bekono F, Lefeuvre-Orfila L, Paris F, Rebillard A. Exercise training improves radiotherapy efficiency in a murine model of prostate cancer. FASEB J. 2020;34:4984–96.PubMedCrossRef
420.
Esteves M, Monteiro MP, Duarte JA. Role of regular physical exercise in tumor vasculature: favorable modulator of tumor milieu. Int J Sports Med. 2021;42:389–406.PubMedCrossRef
421.
McCullough DJ, Stabley JN, Siemann DW, Behnke BJ. Modulation of blood flow, hypoxia, and vascular function in orthotopic prostate tumors during exercise. J Natl Cancer Inst. 2014;106:dju036.PubMedPubMedCentralCrossRef
422.
Schadler KL, Thomas NJ, Galie PA, Bhang DH, Roby KC, Addai P, Till JE, Sturgeon K, Zaslavsky A, Chen CS, et al. Tumor vessel normalization after aerobic exercise enhances chemotherapeutic efficacy. Oncotarget. 2016;7:65429–40.PubMedPubMedCentralCrossRef
423.
Garcia E, Becker VG, McCullough DJ, Stabley JN, Gittemeier EM, Opoku-Acheampong AB, Sieman DW, Behnke BJ. Blood flow responses to mild-intensity exercise in ectopic vs. orthotopic prostate tumors; dependence upon host tissue hemodynamics and vascular reactivity. J Appl Physiol. 2016;121:15–24.PubMedPubMedCentralCrossRef
424.
Jones LW, Dewhirst MW. Therapeutic properties of aerobic training after a cancer diagnosis: more than a one-trick pony? J Natl Cancer Inst. 2014;106:dju042.PubMedPubMedCentralCrossRef
425.
Jones LW, Eves ND, Courneya KS, Chiu BK, Baracos VE, Hanson J, Johnson L, Mackey JR. Effects of exercise training on antitumor efficacy of doxorubicin in MDA-MB-231 breast cancer xenografts. Clin Cancer Res. 2005;11:6695–8.PubMedCrossRef
426.
Florez Bedoya CA, Cardoso ACF, Parker N, Ngo-Huang A, Petzel MQ, Kim MP, Fogelman D, Romero SG, Wang H, Park M, et al. Exercise during preoperative therapy increases tumor vascularity in pancreatic tumor patients. Sci Rep. 2019;9:13966.PubMedPubMedCentralCrossRef
427.
428.
Crnko S, Du Pre BC, Sluijter JPG, Van Laake LW. Circadian rhythms and the molecular clock in cardiovascular biology and disease. Nat Rev Cardiol. 2019;16:437–47.PubMedCrossRef
429.
430.
431.
Sancar A, Lindsey-Boltz LA, Gaddameedhi S, Selby CP, Ye R, Chiou YY, Kemp MG, Hu J, Lee JH, Ozturk N. Circadian clock, cancer, and chemotherapy. Biochemistry. 2015;54:110–23.PubMedCrossRef
432.
433.
434.
Levi F, Benavides M, Chevelle C, Le Saunier F, Bailleul F, Misset JL, Regensberg C, Vannetzel JM, Reinberg A, Mathe G. Chemotherapy of advanced ovarian cancer with 4’-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. J Clin Oncol. 1990;8:705–14.PubMedCrossRef
435.
Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, et al. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. Invest New Drugs. 2019;37:87–97.PubMedCrossRef
436.
Faessel HM, Mould DR, Zhou X, Faller DV, Sedarati F, Venkatakrishnan K. Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies. Br J Clin Pharmacol. 2019;85:2568–79.PubMedPubMedCentralCrossRef
437.
Focan C, Levi F, Kreutz F, Focan-Henrard D, Lobelle JP, Adam R, Dallemagne B, Jehaes C, Markiewicz S, Weerts J, et al. Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. Anticancer Drugs. 1999;10:385–92.PubMedCrossRef
438.
Price TJ, Ross PJ, Hickish T, Tait D, Norman AR, Ford HE, Middleton G, Sumpter K, Hill M, Oates J, et al. Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer. 2004;3:235–42.PubMedCrossRef
439.
Coudert B, Focan C, Genet D, Giacchetti S, Cvickovic F, Zambelli A, Fillet G, Chollet P, Amoroso D, Van Der Auwera J, et al. A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971. Chronobiol Int. 2008;25:680–96.PubMedCrossRef
440.
Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009;27:4068–75.PubMedCrossRef
441.
Qvortrup C, Jensen BV, Fokstuen T, Nielsen SE, Keldsen N, Glimelius B, Bjerregaard B, Mejer J, Larsen FO, Pfeiffer P. A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer. Ann Oncol. 2010;21:87–91.PubMedCrossRef
442.
Li J, Chen R, Ji M, Zou SL, Zhu LN. Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis. Cancer Chemother Pharmacol. 2015;76:651–5.PubMedCrossRef
443.
Re GL, Santeufemia DA, Re FL, Bortolus R, Doretto P, Marus W, Buttazzi L, Lenardon O, Falda A, Piazza R, et al. Interleukin-2 chronotherapy for metastatic renal cell carcinoma: Results of a phase I–II study. Cytokine. 2020;128:154984.PubMedCrossRef
444.
Roosendaal J, Jacobs BAW, Pluim D, Rosing H, de Vries N, van Werkhoven E, Nuijen B, Beijnen JH, Huitema ADR, Schellens JHM, et al. Phase I pharmacological study of continuous chronomodulated capecitabine treatment. Pharm Res. 2020;37:89.PubMedPubMedCentralCrossRef
445.
Levi F, Karaboue A, Gorden L, Innominato PF, Saffroy R, Giacchetti S, Hauteville D, Guettier C, Adam R, Bouchahda M. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemother Pharmacol. 2011;67:339–48.PubMedCrossRef
446.
Farker K, Merkel U, Wedding U, Hippius M, Hoffken K, Hoffmann A. Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation. Int J Clin Pharmacol Ther. 2006;44:31–7.PubMedCrossRef
Metadata
Title
Circadian rhythms and cancers: the intrinsic links and therapeutic potentials
Authors
Li Zhou
Zhe Zhang
Edouard Nice
Canhua Huang
Wei Zhang
Yong Tang
Publication date
01-12-2022
Publisher
BioMed Central
Keyword
Cancer Therapy
Published in
Journal of Hematology & Oncology / Issue 1/2022
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-022-01238-y

Other articles of this Issue 1/2022

Journal of Hematology & Oncology 1/2022 Go to the issue

Research

Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)

Correction

Correction to: COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study

Review

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Research

Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia

Review

Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias

Correspondence

FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits